Skip to main content

Table 1 Baseline characteristics

From: Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

Variables Total Adjuvant chemotherapy cycles  
Not received (A) Received (cycles) P
7–8 or 10–12 cycles (B) 4–6 or 6–9 cycles (C) ≤3 or 5 cycles (D) Total
n 428 86 (20.1) 175 (40.9) 107 (25.0) 60 (14.0) 342 (79.9)  
Age (years)        < 0.001
 Median 60 66 57 60 62 59  
 Range 23–79 38–79 25–78 23–78 41–79 23–79  
Sex        0.458
 Female 124 (29.0) 26 (30.2) 49 (28.0) 27 (25.2) 22 (36.7) 98 (28.7)  
 Male 304 (71.0) 60 (69.8) 126 (72.0) 80 (74.8) 38 (63.3) 244 (71.3)  
BMI        0.046
 Median 23.4 22.7 23.9 22.6 23.8 23.5  
 Range 14.8–32.0 15.9–31.2 16.5–32.0 14.8–31.1 17.1–29.4 14.8–32.0  
Surgical approach        0.409
 Traditional open 128 (29.9) 22 (25.6) 49 (28.0) 37 (34.6) 20 (33.3) 106 (31.0)  
 Laparoscopic-assisted 286 (66.8) 62 (72.1) 121 (69.1) 67 (62.6) 36 (60.0) 224 (65.5)  
 Conversion to open 14 (3.3) 2 (2.3) 5 (2.9) 3 (2.8) 4 (6.7) 12 (3.5)  
Intraoperative blood loss        0.323
  ≤ 100 ml 351 (82.0) 71 (82.6) 137 (78.3) 93 (86.9) 50 (83.3) 280 (81.9)  
 >100 ml 77 (18.0) 15 (17.4) 38 (21.7) 14 (13.1) 10 (16.7) 62 (18.1)  
Postoperative complications        0.001
 Negative 376 (87.9) 65 (75.6) 162 (92.6) 96 (89.7) 53 (88.3) 311 (90.9)  
 Positive 52 (12.1) 21 (24.4) 13 (7.4) 11 (10.3) 7 (11.7) 31 (9.1)  
Tumor length/diameter (cm)        0.010
 Median 4.2 4.2 4.0 4.0 5.0 4.2  
 Range 0.3–19.0 1.5–14.3 0.3–19.0 1.5–14.0 2.0–13.0 0.3–19.0  
Histological type        0.511
 High differentiation adenocarcinoma 3 (0.7) 1 (1.2) 1 (0.6) 0 (0.0) 1 (1.7) 2 (0.6)  
 Median differentiation adenocarcinoma 84 (19.6) 22 (25.6) 31 (17.7) 21 (19.6) 10 (16.7) 62 (18.1)  
 Low differentiation adenocarcinoma 173 (40.4) 26 (30.2) 78 (44.6) 44 (41.1) 25 (41.7) 147 (43.0)  
 Median-Low differentiation adenocarcinoma 132(30.8) 30 (34.9) 47 (26.9) 35 (32.7) 20 (33.3) 102 (29.8)  
 Mucinous adenocarcinoma 14 (3.3) 4 (4.7) 5 (2.9) 3 (2.8) 2 (3.3) 10 (2.9)  
 Signet-ring cell carcinoma 22 (5.1) 3 (3.5) 13 (7.4) 4 (3.7) 2 (3.3) 19 (5.6)  
Vascular tumor embolus        0.080
 Negative 183 (42.8) 46 (53.5) 75 (42.9) 42 (39.3) 20 (33.3) 137 (40.1)  
 Positive 245 (57.2) 40 (46.5) 100 (57.1) 65 (60.7) 40 (66.7) 205 (59.9)  
Depth of Invasion (T)        0.661
 T1 4 (0.9) 0 (0.0) 2 (1.1) 1 (0.9) 1 (1.7) 4 (0.9)  
 T2 46 (10.7) 6 (7.0) 19 (10.9) 15 (14.0) 6 (10.0) 40 (11.7)  
 T3 177 (41.4) 40 (46.5) 74 (42.3) 41 (38.3) 22 (36.7) 137 (40.1)  
 T4a 194 (45.3) 38 (44.2) 78 (44.6) 49 (45.8) 29 (48.3) 156 (45.6)  
 T4b 7 (1.6) 2 (2.3) 2 (1.1) 1 (0.9) 2 (3.3) 5 (1.5)  
Lymph node metastasis (N)        0.092
 N0 91 (21.3) 26 (30.2) 38 (21.7) 18 (16.8) 9 (15.0) 65 (19.0)  
 N1 108 (25.2) 17 (19.8) 43 (24.6) 33 (30.8) 15 (25.0) 91 (26.6)  
 N2 105 (24.5) 26 (30.2) 38 (21.7) 28 (26.2) 13 (21.7) 79 (23.1)  
 N3a 90 (21.0) 11 (12.8) 39 (22.3) 23 (21.5) 17 (28.3) 79 (23.1)  
 N3b 34 (7.9) 6 (7.0) 17 (9.7) 5 (4.7) 6 (10.0) 28 (8.2)  
TNM        0.585
 II 166 (38.8) 37 (43.0) 68 (38.9) 42 (39.3) 19 (31.7) 129 (37.7)  
  IIA 91 (21.3) 20 (23.3) 38 (21.7) 23 (21.5) 10 (16.7)   
  IIB 75 (17.5) 17 (19.8) 30 (17.1) 19 (17.8) 9 (15.0)   
 III 262 (61.2) 49 (57.0) 107 (61.1) 65 (60.7) 41 (68.3) 213 (62.3)  
  IIIA 139 (32.5) 30 (34.9) 54 (30.9) 36 (33.6) 19 (31.7)   
  IIIB 89 (20.8) 13 (15.1) 36 (20.6) 24 (22.4) 16 (26.7)   
  IIIC 34 (7.9) 6 (7.0) 17 (9.7) 5 (4.7) 6 (10.0)   
Serum CEA level        0.184
 ≤ 5 ng/ml 340 (79.4) 65 (75.6) 148 (84.6) 82 (76.6) 45 (75.0) 275 (80.4)  
 >5 ng/ml 88 (20.6) 21 (24.4) 27 (15.4) 25 (23.4) 15 (25.0) 67 (19.6)  
Serum CA199 level        0.272
 ≤ 37 U/ml 371 (86.7) 71 (82.6) 156 (89.1) 95 (88.8) 49 (81.7) 300 (87.7)  
 >37 U/ml 57 (13.3) 15 (17.4) 19 (10.9) 12 (11.2) 11 (18.3) 42 (12.3)  
Recurrence        0.008
 Negative 262 (61.2) 43 (50.0) 119 (68.0) 70 (65.4) 30 (50.0) 219 (64.0)  
 Positive 166 (38.8) 43 (50.0) 56 (32.0) 37 (34.6) 30 (50.0) 123 (36.0)  
Survival        < 0.001
 Alive 283 (66.1) 45 (52.3) 129 (73.7) 77 (72.0) 32 (53.3) 238 (69.6)  
 Dead 145 (33.9) 41 (47.7) 46 (26.3) 30 (28.0) 28 (46.7) 104 (30.4)  
  1. Note: P < 0.05, statistically significant; P values between groups A, B, C and D